LAUSR

Plasma hsa‐mir‐19b is a potential LevoDopa therapy marker

Sign Up to like & get
recommendations!
1 Published in 2021 at "Journal of Cellular and Molecular Medicine"

DOI: 10.1111/jcmm.16827

Abstract: Parkinson's disease (PD) is the second most common neurodegenerative disorder among the elderly, the diagnostic and prognostic of which is based mostly on clinical signs. LevoDopa replacement is the gold standard therapy for PD, as… read more here.

Keywords: hsa mir; levodopa therapy; mir 19b; plasma hsa ... See more keywords